Nature Communications (Oct 2022)

Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12

  • Zixiang Wang,
  • Shourong Wang,
  • Junchao Qin,
  • Xiyu Zhang,
  • Gang Lu,
  • Hongbin Liu,
  • Haiyang Guo,
  • Ligang Wu,
  • Victoria O. Shender,
  • Changshun Shao,
  • Beihua Kong,
  • Zhaojian Liu

DOI
https://doi.org/10.1038/s41467-022-34042-w
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 18

Abstract

Read online

Altered expression of splicing factors can contribute to tumour progression. Here the authors show that splicing factor BUD31 enhances ovarian cancer progression by promoting exon inclusion in the anti-apoptotic BCL2 family member, BCL2L12.